JP2014523913A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523913A5
JP2014523913A5 JP2014521732A JP2014521732A JP2014523913A5 JP 2014523913 A5 JP2014523913 A5 JP 2014523913A5 JP 2014521732 A JP2014521732 A JP 2014521732A JP 2014521732 A JP2014521732 A JP 2014521732A JP 2014523913 A5 JP2014523913 A5 JP 2014523913A5
Authority
JP
Japan
Prior art keywords
cancer
cancer cell
cell
cancer cells
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523913A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/047198 external-priority patent/WO2013012922A1/en
Publication of JP2014523913A publication Critical patent/JP2014523913A/ja
Publication of JP2014523913A5 publication Critical patent/JP2014523913A5/ja
Pending legal-status Critical Current

Links

JP2014521732A 2011-07-20 2012-07-18 抗がん治療法で用いるためのアデノウイルスe1a断片 Pending JP2014523913A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509891P 2011-07-20 2011-07-20
US61/509,891 2011-07-20
PCT/US2012/047198 WO2013012922A1 (en) 2011-07-20 2012-07-18 Adenovirus e1a fragments for use in anti-cancer therapies

Publications (2)

Publication Number Publication Date
JP2014523913A JP2014523913A (ja) 2014-09-18
JP2014523913A5 true JP2014523913A5 (https=) 2015-09-10

Family

ID=47556185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521732A Pending JP2014523913A (ja) 2011-07-20 2012-07-18 抗がん治療法で用いるためのアデノウイルスe1a断片

Country Status (4)

Country Link
US (1) US8716014B2 (https=)
EP (1) EP2734219B1 (https=)
JP (1) JP2014523913A (https=)
WO (1) WO2013012922A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190276499A1 (en) * 2016-06-22 2019-09-12 The Children's Hospital Of Philadelphia Protein VII Fragments and Methods of Use Thereof for the Treatment of Inflammatory Disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
WO1997035012A1 (en) * 1996-03-20 1997-09-25 Board Of Regents, The University Of Texas System Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US7883888B2 (en) * 2000-04-05 2011-02-08 The Research Foundation —The State University of New York Peptides selectively lethal to malignant and transformed mammalian cells
US7294704B2 (en) * 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
KR100972618B1 (ko) * 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 her2 과발현 세포를 검출하는방법

Similar Documents

Publication Publication Date Title
Jiang et al. Connexin and pannexin channels in cancer
KR102164876B1 (ko) IL­12 및 shVEGF 동시발현 아데노바이러스를 포함하는 항종양 면역성 증진 조성물
Chen et al. PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1
Ortiz et al. New gene therapy strategies for cancer treatment: a review of recent patents
Wang et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy
Liao et al. Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway
Lojkin et al. Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer
Liu et al. circGFRA1 promotes ovarian cancer progression by sponging miR-449a
Wang et al. A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer
Zhou et al. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer
Shi et al. Bone marrow‐derived mesenchymal stem cells promote Helicobacter pylori‐associated gastric cancer progression by secreting thrombospondin‐2
Chen et al. Establishing of mouse oral carcinoma cell lines derived from transgenic mice and their use as syngeneic tumorigenesis models
JP2015516370A5 (https=)
JP2020516293A5 (https=)
Liu et al. An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression
Kim et al. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation
Mirzaei et al. Overexpression of MDA-7/IL-24 as an anticancer cytokine in gene therapy of thyroid carcinoma
Liu et al. Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma
Shang et al. ZnPPIX inhibits peritoneal metastasis of gastric cancer via its antiangiogenic activity
JP2014523913A5 (https=)
Tada et al. A potential therapeutic strategy for malignant mesothelioma with gene medicine
Gao et al. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA
Yamanouchi et al. The Wilms' tumor gene WT1− 17AA/− KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in vivo ovarian cancer model
Guo et al. Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model
Hsiao et al. The myoepithelial cell layer may serve as a potential trigger factor for different outcomes of stage-matched invasive lobular and ductal breast cancers